NCT07360964

Brief Summary

Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at P50-P75 for not_applicable

Timeline
1mo left

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Sep 2025Jun 2026

Study Start

First participant enrolled

September 10, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

January 8, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 22, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Expected
Last Updated

January 22, 2026

Status Verified

January 1, 2026

Enrollment Period

4 months

First QC Date

January 8, 2026

Last Update Submit

January 14, 2026

Conditions

Chondrosarcoma

Keywords

clear cell chondrosarcomaprognosis

Outcome Measures

Primary Outcomes (1)

  • Prognostic accuracy

    Ability of the model to predict overall survival, measured by AUC/C-index

    At baseline

Study Arms (1)

Patients

EXPERIMENTAL

Patients with a diagnosis of clear cell chondrosarcoma

Genetic: Molecular studies

Interventions

Molecular studiesGENETIC

Molecolar studies to define possible prognostic parameters

Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female patients with diagnosis of clear cell chondrosarcoma and chondrosarcoma with a clear cell component treated from 01 Jan 1982 to 31 Dec 2023
  • Information available (date of primary tumor diagnosis, local treatments, systemic treatment, response to systemic treatment, date of progression) and date and status at last follow-up
  • Imaging studies available for revision
  • Histological slides available for revision

You may not qualify if:

  • \- Diagnosis different from clear cell chondrosarcoma or chondrosarcoma with a clear cell component;
  • Absence of radiological and/or clinical data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCC Rizzoli Orthopedic Institute

Bologna, 40136, Italy

Location

MeSH Terms

Conditions

ChondrosarcomaChondrosarcoma, Clear Cell

Condition Hierarchy (Ancestors)

Neoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcoma

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 8, 2026

First Posted

January 22, 2026

Study Start

September 10, 2025

Primary Completion

December 31, 2025

Study Completion (Estimated)

June 30, 2026

Last Updated

January 22, 2026

Record last verified: 2026-01

Locations

IT(1)